A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRigshospitalet, Denmark

About this trial

DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.

Age ≥18 years

LVEF >35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.

Disqualifiers

Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)

Previous CABG within the last 3 months before index hospitalization

Life expectancy less than 1 year or severe neurologic outcome

Unable or unwilling to give informed consent

Trial design

Design model

Parallel

Treatments tested in this trial

  • Implantable cardioverter defibrillator

    Device

    Implantation of an ICD for secondary prevention

Treatment groups

1,200 Participants
are divided into 2 treatment groups
Group A: ICD-implantationExperimental treatment 1 intervention
Group B: Standard careNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

All-cause mortality

The clinical event committee will aim to attribute the cause of death to the underlying disease process rather than the immediate mechanism. Mortality will be classified as cardiovascular and non-cardiovascular.

Time frame
5 years

Secondary outcomes

1

All cause mortality

Time frame
1 year
2

Sudden cardiovascular death

Cardiovascular death fulfilling the following criteria: * In witnessed cases a change in cardiovascular status with time until death being \<1 hour. * In unwitnessed cases \<24 hours since last seen alive and functioning normal.

Time frame
1 year
3

Cardiovascular death

Mortality is considered as cardiovascular unless it is clearly attributable to another cause and thus includes: * Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure). * Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease. * All procedure-related deaths, including those related to a complication of the ICD-procedure or treatment for a complication of the procedure. * All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events. * Death of unknown or cardiac cause.

Time frame
1 year

Other outcomes

1

Device revision or replacement due to infection or malfunction

Explorative outcome

Time frame
1 year
2

Appropriate shock from an ICD (successfully treated VT/VF)

Explorative outcome

Time frame
1 year
3

Inappropriate shock from an ICD (shock on non-VT/VF)

Explorative outcome

Time frame
1 year
4

Register-based all cause mortality

Time frame
10 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.